Clinical Trials Browser

Active not recruiting × Mitomycin × Genitourinary × Clear all

NCT03775265 2026-03-18

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

475 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06211764 2026-03-17

SunRISe-5

Phase 3 Active not recruiting

272 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06331299 2026-01-15

UTOPIA

Phase 3 Active not recruiting

99 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

95 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT02106572 2025-07-23

TIM

Phase 3 Active not recruiting

548 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT02710734 2024-12-24

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2 Active not recruiting

78 enrolled

Genitourinary

Urothelial Carcinoma of the Bladder

NCT04241185 2024-11-25

MK-3475-992

Phase 3 Active not recruiting

520 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05243550 2024-11-04

ENVISION

Phase 3 Active not recruiting

240 enrolled 20 charts 1 FDA

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06462001 2024-06-17

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Phase 3 Active not recruiting

500 enrolled

Genitourinary

Carcinoma, Transitional Cell